Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.01814-20 http://scihub22266oqcxt.onion/10.1128/AAC.01814-20 33139290!7927874!33139290     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antimicrob+Agents+Chemother 2020 ; 65 (1): ä Nephropedia Template TP {{tp|p=33139290|t=2020. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 |pdf=|usr=}}{{33139290}} gab.com Text New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33139290 #FOAvip Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury, and decreased levels of viral RNA. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of faster time to recovery in patients with severe COVID-19 and higher odds of improved clinical status in patients with moderate COVID-19. Here, clinical trials published to date are presented and appraised. Remdesivir's potential benefits and its favorable adverse-event profile make it an option for the treatment of COVID-19. This article examines the available literature describing remdesivir's pharmacology, pharmacokinetics, and preclinical and clinical data. Twit Text FOAVip New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33139290 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33139290 #FOAvip English Wikipedia <ref>{{Cite pmid|33139290}}</ref> New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 #MMPMID33139290 Aleissa MM; Silverman EA; Paredes Acosta LM; Nutt CT; Richterman A; Marty FM Antimicrob Agents Chemother 2020[Dec]; 65 (1): ä PMID33139290show ga Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury, and decreased levels of viral RNA. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of faster time to recovery in patients with severe COVID-19 and higher odds of improved clinical status in patients with moderate COVID-19. Here, clinical trials published to date are presented and appraised. Remdesivir's potential benefits and its favorable adverse-event profile make it an option for the treatment of COVID-19. This article examines the available literature describing remdesivir's pharmacology, pharmacokinetics, and preclinical and clinical data. |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics/pharmacology[MESH] |Alanine/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics/pharmacology[MESH] |Animals[MESH] |Antiviral Agents/*administration & dosage/chemistry/pharmacokinetics/*pharmacology[MESH] |Breast Feeding[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/drug therapy/prevention & control[MESH] |Female[MESH] |Humans[MESH] |Immunocompromised Host[MESH] |Middle East Respiratory Syndrome Coronavirus/drug effects[MESH] |Pregnancy[MESH]New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COV(epmc).pdf DeepDyve Pubget Overpricing